Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Will Hedge Funds’ Pivot to Private Markets Help or Hurt Them? John Crabb Premium Third Point Boosts Market Bets in May Stephen Taub Hurricane Season: Insurance-linked Securities and Navigating Non-financial Risks Sponsored by Schroders Capital